Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vertex Pharmaceuticals
(NQ:
VRTX
)
401.08
+0.92 (+0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
Next >
Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
November 04, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
November 03, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Third Quarter 2022 Financial Results
October 27, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Announce Third Quarter 2022 Financial Results on October 27
October 13, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
October 11, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Shares Higher On Optimism About CRISPR Partnership
October 05, 2022
Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments.
Via
MarketBeat
Exposures
Product Safety
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
September 27, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Appoints Jonathan Biller as Chief Legal Officer
September 08, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
September 02, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
September 01, 2022
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. That’s why BioRestorative...
Via
TheNewswire.com
Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9
August 31, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Advances VX-548 in Acute and Neuropathic Pain
July 22, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Announce Second Quarter 2022 Financial Results on August 4
July 18, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
July 11, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
July 05, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
June 11, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
June 10, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
June 08, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
June 08, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
June 06, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
June 02, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
May 31, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Vertex Pharmaceuticals Incorporated with Losses of $100,000 to Contact the Firm
May 27, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Vertex Pharmaceuticals Incorporated with Losses of $100,000 to Contact the Firm
May 26, 2022
From
The Schall Law Firm
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Vertex Pharmaceuticals Incorporated Investors with Losses to Inquire About Class Action Investigation – VRTX
May 26, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
Suketu Upadhyay Elected to Vertex Board of Directors
May 18, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies
May 17, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
May 17, 2022
From
Vertex Pharmaceuticals
Via
Business Wire
Vertex Reports First Quarter 2022 Financial Results
May 05, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.